Cardiology

Dr. Gregory Weiss offers perspective on a recent guideline update from the American Heart Association outlining strategies to best manage risk of cardiovascular disease in women entering menopause.

There were similar rates of primary outcome events in the high-dose and standard-dose vaccination groups.

An analysis of more than 7k patients with CAN data from the ACCORD trial suggest intensive blood pressure and blood glucose control could reduce risk of cardiovascular autonomic neuropathy.

Learn more about the importance of educating patients on the differences between store-bought fish oil supplements and therapies derived from omega-3 such as icosapent ethyl (Vascepa).

Despite these findings, there is still uncertainty as to whether mitigating symptoms of depression can lower cardiovascular risk.

The agency is expected to rule on the Novartis treatment in 2021.

The FDA's Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 12 to 1 in favor of an indication for sacubitril/valsartan (Entresto) during a December 15 meeting.

Dr. Paul Thompson reflects on the diagnosis and treatment of hypertrophic cardiomyopathy and other comorbid conditions, in this column, titled "Don’t Be Thick Headed With Thick Hearts".

An analysis of more than 25 studies with more than 1 million patients is giving an overview of how the timing of a diabetes diagnosis can impact risk of complications later in life.

Results of CardioLink-9 suggest icosapent ethyl could provide symptom relief and reduce inflammation in patients with COVID-19.

An analysis of more than 7k patients from Brazil suggests high blood pressure at any age and for any amount of time was linked to accelerated cognitive decline later in life.

An analysis of 2 major studies is comparing the effects of bariatric surgery vs standard medical therapy on risk of cardiovascular disease events in obese teens with type 2 diabetes.

Dr. Gregory Weiss explores and gives perspective on the latest guidelines from the AHA and ACC outlining quality measures for adults with atrial fibrillation or atrial flutter

A resident from Penn State Hershey Medical Center offers perspective on the idea of using SGLT2 inhibitors for primary prevention in patients with type 2 diabetes.

A comparison of data from Teen-LABS and TODAY offer insight into the effects of medical therapy alone vs bariatric surgery in obese teens with type 2 diabetes.

There is concern over whether or not patients are adhering to their treatment during the pandemic.

An analysis of data from more than 900k Veterans suggests use of SSRIs in those with PTSD was associated with an increased risk of hemorrhagic stroke.

Dr. Gerald Shulman discusses how diabetes can eventually be reversed.

An analysis of data from Geisinger suggests living closer to fracking activity could increase a person's risk of hospitalization for heart failure.

By addressing insulin resistance, researchers believe they can reduce the comorbidities associated with type 2 diabetes.

Dr. Giorgino discusses how combining SGLT2 Inhibitors and GLP-1RA could be combined for treating type 2 diabetes.

A resident from Penn State Hershey Medical Center offers his perspective on the potential of the SGLT2 inhibitor class to transform the treatment of diabetes and cardiovascular disease among patients with diabetes.

Results of the INVESTED trial offer clinicians into the effects of high-dose versus standard-dose influenza vaccines in patients with high-risk cardiovascular disease.

Check out our latest case report from Brady Pregerson, MD, which features a man in his 90s presenting to the ED with fatigue similar to what he had during a diverticular bleed less than 2 weeks prior.

An analysis of data from the Look AHEAD study details the associations between long-term variability of glycemic markers and increased risk of all-cause and cardiovascular mortality.